Elanco Animal Health (ELAN) Long-Term Debt Issuances (2018 - 2025)

Elanco Animal Health (ELAN) reported Long-Term Debt Issuances of $2.1 billion for Q4 2025, up 321.2% sequentially from $500.0 million in Q3 2021.

Elanco Animal Health (ELAN) Long-Term Debt Issuances (2018 - 2025) Analysis & Trends

Elanco Animal Health (ELAN) has 5 years of Long-Term Debt Issuances data on file, last reported at $2.1 billion in Q4 2025.

For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $2.1 billion; the trailing twelve-month figure through Dec 2025 stood at $2.1 billion (changed N/A YoY), and the FY2025 full-year result was $2.1 billion, up 501.71% from the prior year.
Long-Term Debt Issuances advanced to $2.1 billion in Q4 2025, from $500.0 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $2.1 billion in Q4 2025 to a low of $500.0 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	-
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	3.64 Bn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	-
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	-
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	-
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	-
10	Vireo Growth	10.53 Bn	10.38 Bn	59.30 Mn	4.50 Mn

Download Data